Marshall Urist, EVP, Research & Investments at Royalty Pharma, sold RPRX on Oct 5, 2026
Data as of Oct 16
- Traded
- Oct 5, 2026
- Disclosed
- Oct 5, 2026
- Filed
- The same day
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
RPRX since disclosure
+7.6%
after the sale
Similar stocks (XLV) since disclosure
+5.6%
XLV — its sector index fund
Change in closing price from Oct 5, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.